See the latest news and media coverage for Novartis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Innovative medicines company
novartis.comLast updated
In short: Novartis achieved significant clinical and regulatory milestones, returning to sales growth while expanding its oncology and renal drug portfolios.
The approval expands Pluvicto's use to PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling eligible patients. Phase III PSMAddition showed 33% risk reduction in progression or death.
Net sales rose 1% cc, with core operating income flat. Priority brands like Kisqali and Kesimpta drove growth.
Fabhalta is the first complement inhibitor to slow kidney function decline in primary IgAN, with 48% reduction in eGFR decline over two years
The deal, worth up to $1.5bn, adds a novel ADC payload platform and two lead assets targeting solid tumors.
"This approval signals a new era in the treatment of prostate cancer, representing a shift toward more targeted, early intervention," said Prostate Cancer Foundation Chief...
The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs.
Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is proud to announce that Health Canada has issued a Notice of Compliance (NOC) for RHAPSIDO® (remibrutinib tablets) for...
Novartis celebrates 30 years of merger, while EMA recommends generics for Jakavi. The stock remains stable despite this.
Track Novartis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novartis and other trending companies.